Status:
COMPLETED
A Study of Induction and Maintenance Treatment With MabThera (Rituximab) in Patients With Indolent B-Cell Nonfollicular Lymphomas
Lead Sponsor:
Hoffmann-La Roche
Conditions:
Non-Hodgkin's Lymphoma
Eligibility:
All Genders
18-65 years
Phase:
PHASE2
Brief Summary
This study will evaluate the efficacy and safety of MabThera in combination chemotherapy, followed by maintenance treatment with MabThera. The anticipated time on study treatment is 1-2 years, and the...
Eligibility Criteria
Inclusion
- adult patients 18-65 years of age;
- previously untreated indolent nonfollicular non-Hodgkin's lymphoma;
- active disease;
- \>=3 involved sites.
Exclusion
- typical chronic lymphocytic leukemia;
- other malignancies within 3 years before study, except basal or squamous cell skin cancer or cancer in situ of the cervix;
- systemic corticosteroid use for \>1 month;
- significant cardiovascular disease;
- central nervous system involvement;
- hepatitis B or C virus infection, or HIV infection.
Key Trial Info
Start Date :
July 20 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 24 2010
Estimated Enrollment :
47 Patients enrolled
Trial Details
Trial ID
NCT01153971
Start Date
July 20 2005
End Date
September 24 2010
Last Update
August 1 2017
Active Locations (15)
Enter a location and click search to find clinical trials sorted by distance.
1
Ospedale Civile Dello Spirito Santo; Divisione Di Ematologia
Pescara, Abruzzo, Italy, 65100
2
Ospedale Civile; Divisione Di Oncologia
Pescara, Abruzzo, Italy, 65124
3
Ospedale Oncologico Regionale; U.O. Oncologia Medica Ed Ematologia
Rionero in Vulture, Basilicate, Italy, 85028
4
Ospedale Riuniti; Divisione Di Ematologia
Reggio Calabria, Calabria, Italy, 89100